Sai Parenterals Live Share Price Today, Share Analysis and Chart

Pharmaceuticals company Sai Parenterals announced Q2FY27 results Consolidated Financial Highlights: Total income stood at Rs 1,986.37 million in Q2FY27, up 8.89% QoQ from Rs 1,824.13 million in Q1FY27 and up 262.06% YoY from Rs 548.63 million in Q2FY26. For H1FY27, Total income reached Rs 3,810.50 million, up 326.10% YoY from Rs 894.27 million in H1FY26. Revenue from operations was Rs 1,949.18 million in Q2FY27, growing 9.09% QoQ compared to Rs 1,786.72 million in Q1FY27 and growing 264.14% YoY compared to Rs 535.28 million in Q2FY26. For H1FY27, Revenue from operations stood at Rs 3,735.90 million, showing a YoY growth of 329.82% from Rs 869.18 million in H1FY26. Profit before tax (PBT) recorded Rs 98.89 million in Q2FY27, registering a QoQ increase of 1.01% from Rs 97.90 million in Q1FY27 and a YoY increase of 8.03% from Rs 91.54 million in Q2FY26. For H1FY27, PBT reached Rs 196.79 million, rising 76.35% YoY against Rs 111.59 million in H1FY26. Profit after tax (PAT) reached Rs 105.10 million in Q2FY27, showing a QoQ growth of 32.65% from Rs 79.23 million in Q1FY27 and a YoY growth of 65.51% from Rs 63.50 million in Q2FY26. For H1FY27, PAT stood at Rs 184.33 million, showing an increase of 137.42% YoY against Rs 77.64 million in H1FY26. Earnings per equity share (EPS) after exceptional items was Rs 2.38 in Q2FY27, rising 32.96% QoQ from Rs 1.79 in Q1FY27 and climbing 395.83% YoY from Rs 0.48 in Q2FY26. For H1FY27, basic and diluted EPS stood at Rs 4.17, up 47.87% YoY compared to Rs 2.82 in H1FY26. Standalone Financial Highlights: Total income reached Rs 565.01 million in Q2FY27, reflecting a QoQ rise of 0.55% from Rs 561.92 million in Q1FY27 and a YoY rise of 16.73% from Rs 484.05 million in Q2FY26. For H1FY27, standalone Total income was Rs 1,126.93 million, increasing 63.68% YoY from Rs 688.48 million in H1FY26. Revenue from operations stood at Rs 529.09 million in Q2FY27, increasing 0.25% QoQ over Rs 527.79 million in Q1FY27 and increasing 10.74% YoY over Rs 477.79 million in Q2FY26. For H1FY27, Revenue from operations recorded Rs 1,056.87 million, which is a YoY growth of 57.79% against Rs 669.80 million in H1FY26. Profit before tax (PBT) came in at Rs 86.97 million in Q2FY27, down 26.48% QoQ from Rs 118.30 million in Q1FY27 but up 6.44% YoY from Rs 81.71 million in Q2FY26. For H1FY27, PBT reached Rs 205.27 million, exhibiting a 119.24% YoY growth compared to Rs 93.63 million in H1FY26. Profit after tax (PAT) was Rs 64.86 million in Q2FY27, declining 26.92% QoQ from Rs 88.75 million in Q1FY27 but improving 15.02% YoY against Rs 56.39 million in Q2FY26. For H1FY27, PAT stood at Rs 153.61 million, marking a YoY growth of 137.64% over Rs 64.64 million in H1FY26. Earnings per equity share (EPS) stood at Rs 1.47 in Q2FY27, down 26.87% QoQ from Rs 2.01 in Q1FY27 but up 250.00% YoY from Rs 0.42 in Q2FY26. For H1FY27, standalone basic and diluted EPS was Rs 3.48, higher by 48.09% YoY from Rs 2.35 in H1FY26. Anil Kumar Karusala, Chairman & Managing Director, Sai Parenterals, said: Q2FY27 is the quarter in which our transformation began to show in our profitability. Consolidated revenue from operations rose 9% sequentially to Rs 196 crore. H1FY27 revenue stood at Rs 376 crore, half of our FY27 target of Rs 750 crore and ahead of our guided 45:55 phasing across H1 & H2. Gross margin rose sequentially from 40.9% to 47.5%, driven by tighter inventory management. We worked through higher-cost inventory carried from earlier periods and introduced strict first-in, first-out controls on a new ERP system, which brought inventory levels down materially. We see room to move gross margin towards 50%. EBITDA grew 67% sequentially to Rs 41 crore, a margin of 21.1% against 13.7% in Q1FY27. H1FY27 EBITDA margin stands at 17.6%, already ahead of the 17% we guided for the year. Depreciation and amortisation rose to Rs 25 crore from Rs 8 crore in Q1FY27, driven by the capitalisation of the Unit III expansion and of Noumed assets, the consolidation of Saicriti Pharma, and amortisation of molecules acquired from Sai Prathyak Laboratories. Despite this, profit before tax held steady quarter-on-quarter. Profit after tax was Rs 11 crore for the quarter and Rs 18 crore for the first half. Australia accounted for 76% of export revenue, against 83% in Q1. In Q1, Sai had supplied additional volumes to Noumed when third-party contract manufacturers fell short. We plan our export capacity broadly 70:30 between Australia and other markets. In the Philippines, we added 11 molecules and 22 SKUs during the quarter. Our capex projects are progressing as planned. The Unit III expansion is complete, taking capacity from 85.5 to 155 million units a month. Output ramps up from Q4FY27, with most of the additional volume serving Australia and New Zealand. Our Adelaide facility begins operations in January 2027, with commercial supply expected from around April. Until then, we will support it with bulk tablets from India. We have completed the acquisition of 60% of Saicriti Pharma, where construction will now accelerate towards completion in July 2027. We have also completed the acquisition of Sai Prathyak Laboratories. All Group R&D; now sits there, and it will begin taking external CDMO development contracts over the next two quarters, with revenue from FY28. With H1 ahead of plan and the second half seasonally our stronger period, we are well placed for FY27. FY27 remains a year of building, and FY28 is when that build should begin to show in our performance. Result PDF

Investor Presentation for the quarter and half year ended 30th September, 2026

Investor press release on standalone and consolidated unaudited financial results for the quarter ended 30th September, 2026.

Statement of variation and deviation for the period ended 30th September, 2026

Financial Results